Navigation Links
Federal Court Asked to Compel Decision in Marijuana Scheduling Action
Date:5/24/2011

WASHINGTON, May 24, 2011 /PRNewswire-USNewswire/ -- A coalition of advocacy groups and patients yesterday filed suit in the U.S. Court of Appeals for the District of Columbia Circuit to compel the Obama Administration to formally respond to a 9-year-old petition to have marijuana rescheduled under the provisions of the Controlled Substances Act (CSA).

Relief sought from the Court of Appeals would enable states with medical marijuana laws to expedite efforts to change marijuana's status under federal law and narrow the widening gap between state and federal law.  For example, Washington Governor Chris Gregoire has expressed interest in having all the states that allow medical marijuana to ask the federal government to reclassify the drug.  If the Court of Appeals grants the relief requested by the CRC, Washington and other medical marijuana states would have the opportunity to seek rescheduling now in expedited proceedings, rather than wait years for a new rescheduling action to ripen.

The Coalition for Rescheduling Cannabis (CRC) argues that marijuana no longer satisfies the requirements of a Schedule I prohibited substance and that federal law requires that it be reclassified.  President Obama's Administration has had ample time to review the Coalition's administrative petition but has refused to take final action, violating the requirements of the Administrative Procedures Act which requires action within a reasonable period of time.

One of the requirements for maintaining a drug in Schedule I of the CSA is that it must not have accepted medical use in the United States.  Marijuana's medical use is now accepted by 16 states (Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington) as well as the District of Columbia.

According to Jon Gettman, coordinator of the CRC, "Marijuana has accepted medical use in the United States, it has a lower abuse potential than drugs like heroin, methamphetamine, and cocaine, and it is safe for use under medical supervision.  All of these characteristics are well-documented scientifically and legally.  Federal law requires the Obama Administration to reclassify marijuana."

"The federal government's strategy has been delay, delay, delay," said Joe Elford, Chief Counsel of ASA and lead counsel on the writ. "It is far past time for the government to answer our rescheduling petition, but unfortunately we've been forced to go to court in order to get resolution." The writ of mandamus filed accuses the government of unreasonable delay in violation of the Administrative Procedures Act.

A formal rejection of the CRC petition would enable the group to take the issue to the federal courts.  Gettman believes that, "The Obama Administration's refusal to act on this petition is an irresponsible stalling tactic; it denies us due process under the law and, more shamefully, it continues to deny countless patients a chance to use current law to seek legal access to marijuana for medical use."

The CSA classifies marijuana and other drugs in various schedules.  Marijuana is currently classified as a Schedule I substance, designating it as having a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. 

The CSA provides a procedure to have scheduling classifications changed in response to scientific research and other relevant factors, such as recognition of a drug's accepted medical use and its dependence liability as compared to other controlled substances.  Schedule I substances include heroin, GHB and MDMA (ecstasy).  Cocaine and oxycodone are both Schedule II substances, which allows for severely restricted medical use while maintaining the assertion that its abuse may lead to severe physiological and psychological dependence.  Marinol® a synthetic form of THC (marijuana) that is widely prescribed medically is a Schedule III substance designating that it has a currently accepted medical use in the United States and that's its abuse is associated with only a moderate dependence liability.

The members of the Coalition for Rescheduling Cannabis include the American Alliance for Medical Cannabis, Americans for Safe Access (ASA), California NORML, the Drug Policy Forum of Texas, High  Times, Los Angeles Cannabis Resource Center (Cooperative), the National Organization for the Reform of Marijuana Laws (NORML), New Mexicans for Compassionate Use, Oakland Cannabis Buyers Cooperative, and Patients Out of Time.

Further information:

Timeline of Efforts to Reschedule Marijuana

  • 1995 2001 – Prior attempt by Jon Gettman to reschedule cannabis ended with a rejection of the petition by then DEA head Asa Hutchinson
  • 2002 – Coalition for Rescheduling files new petition to DEA to reschedule marijuana.
  • 2003 – 2006 – HHS reviews all science relevant and makes recommendation to DEA
  • 2006 – Present – Coalition for Rescheduling Cannabis awaits final decision by DEA.

Writ filed: http://AmericansForSafeAccess.org/downloads/CRC_Writ.pdf

CRC rescheduling petition: http://www.drugscience.org/PDF/Petition_Final_2002.pdf

Additional Information: http://www.drugscience.org


'/>"/>
SOURCE DrugScience.org
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot
4. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
5. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
6. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
7. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
8. Faced With Federal Prosecution, MountainView Agrees to Stop Harassment of RNs in Settlement With Labor Board
9. Malaria Experts Call on Federal Government to Increase Support for Research and Development
10. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
11. Chesley Files Federal Zicam Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):